Actinium Pharmaceuticals Inc (ATNM) Receives New Coverage from Analysts at Maxim Group
Maxim Group initiated coverage on shares of Actinium Pharmaceuticals Inc (AMEX:ATNM) in a research report sent to investors on Thursday. The firm issued a buy rating and a $3.00 target price on the stock.
Shares of Actinium Pharmaceuticals (AMEX ATNM) traded up 2.366% during mid-day trading on Thursday, reaching $0.649. 416,709 shares of the company were exchanged. The company’s 50 day moving average price is $0.62 and its 200 day moving average price is $1.16. Actinium Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $2.15. The firm’s market capitalization is $51.93 million.
TRADEMARK VIOLATION NOTICE: “Actinium Pharmaceuticals Inc (ATNM) Receives New Coverage from Analysts at Maxim Group” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/15/actinium-pharmaceuticals-inc-atnm-receives-new-coverage-from-analysts-at-maxim-group.html.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.